Digital Interventions for Mild Cognitive Impairment
(MediDream Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new type of digital meditation called MediTrain to determine if it can improve thinking skills and sleep in people with mild cognitive impairment (MCI), which involves early memory and thinking problems. The researchers aim to discover if MediTrain significantly enhances cognitive abilities compared to those without cognitive issues. Individuals who move comfortably, have good vision and hearing, and speak English fluently, but have no serious neurological or psychiatric conditions, might be suitable for this trial. As an unphased study, this trial provides a unique opportunity to contribute to innovative research that could enhance cognitive health.
Will I have to stop taking my current medications?
You will need to stop taking anti-depressants and anti-anxiety medications to participate in this trial.
What prior data suggests that this digital intervention is safe for individuals with mild cognitive impairment?
Research on MediTrain, the digital meditation tool being tested, remains in the early stages, so limited safety information is available. The trial is in the "Not Applicable" phase, indicating that the treatment is new or still undergoing early research. This phase often means less safety information compared to more advanced treatments.
However, as a digital meditation program, it is likely low-risk. Meditation practices generally do not cause serious side effects. Most people may find it easy to use and may experience benefits such as reduced stress or improved focus. No negative effects have been reported specifically linked to MediTrain yet. Researchers will closely monitor any effects if participants join the trial.12345Why are researchers excited about this trial?
MediTrain is unique because it leverages digital interventions to address mild cognitive impairment, setting it apart from traditional medications or therapies that often focus on pharmacological approaches. Unlike standard treatments that might involve drugs with potential side effects, MediTrain uses technology to enhance cognitive function through a series of personalized, brain-training exercises. Researchers are excited about this treatment because it offers a non-invasive, customizable approach that could improve cognitive performance without the need for medication, making it a promising option for those seeking alternative or adjunctive therapies.
What evidence suggests that MediTrain might be an effective treatment for mild cognitive impairment?
Research has shown that certain activities can improve brain function in people with mild cognitive impairment (MCI). One study found that these activities led to better results on brain tests for individuals with MCI. Exercise has also been shown to enhance thinking skills in people with MCI more effectively than in those with more severe memory issues. In this trial, participants will use the digital tool MediTrain, which incorporates meditation and is believed to further enhance these improvements. By leveraging technology, MediTrain aims to boost brain health and improve sleep.678910
Who Is on the Research Team?
David Ziegler, PhD
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
This trial is for older adults who are experiencing mild cognitive impairment. Participants should be interested in testing digital interventions aimed at improving cognition, wellbeing, stress levels, and sleep quality.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo treatment with a novel form of closed-loop digital meditation (MediTrain) to improve cognitive abilities and sleep quality
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at immediate and 6-month follow-up
What Are the Treatments Tested in This Trial?
Interventions
- MediTrain
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
National Institute on Aging (NIA)
Collaborator